Erythropoietin for Infants With Brain Injuries Due to Oxygen Deprivation at Birth

Status unconfirmed · Phase 1

Conditions studied: Asphyxia

In brief

Erythropoietin (Epo) is a hormone normally found in the body that may protect brain cells from damage due to lack of oxygen. This study will evaluate the safety of high-dose Epo in infants who did not get enough oxygen during birth.

Key facts

Study ID

NCT00491413

Run by

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

People needed

15

Last updated by the study team

2007-06-26

Who can join

Age: any, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Infant 6 hours of age or less
• Apgar scores less than or equal to 3 at 1 and 5 minutes
• Weight greater than 2500 grams (5.5 lbs)
• Central venous line in place

You may not qualify if…

• infants are ineligible if they do not meet the inclusion criteria above

Where it is running

• All Children's Hospital — St. Petersburg, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.